Epidemiological data indicate that the overall prevalence of PD is around 1.5% with no gender differences; the prevalence increases with the age 2, 3 . The neuropathological background of PD is the progressive selective degeneration of dopaminergic neurons in the substantia nigra 4 . However, as our understanding of the pathophysiological process of PD has improved, it has become evident that, besides the dopaminergic system, the cholinergic, serotoninergic, noradrenergic and glutamatergic systems are also affected. Glutamate is the main excitatory neurotransmitter in the human brain, but the excessive stimulation of glutamatergic receptors may lead to neuronal damage, a process known as excitotoxicity. The gold standard of PD therapy currently remains dopamine (DA) replacement with oral levodopa, which offers good symptomatic relief for the motor symptoms, but can be associated with therapy-related complications such as levodopa-induced dyskinesia (LID) or impulse control disorders (ICDs). Non-motor symptoms (NMs) of PD are often unrecognized and undertreated, although they may have a serious impact on the quality of life. They often precede the development of motor symptoms and their frequency increases in parallel with the progression of PD 13, 14 . NMs can be classified into four main groups: autonomic symptoms, sensory symptoms, sleep disorders and neuropsychiatric symptoms (Table 1. ). ICDs include pathological gambling, hypersexuality, compulsive shopping and binge eating.
Gambling and hypersexuality show a male predominance, while compulsive shopping and eating are more frequent among female PD patients 15, 16 . . GRIN2B is responsible for the synthesis of the NR2B subunit of NMDA receptors, which is the predominant form of the striatal NMDA receptors. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
The kynurenine pathway and its interaction with the dopaminergic system
The kynurenine pathway (KP) is the main route of the tryptophan (Trp) metabolism, responsible for more than 95% of Trp degradation (Fig. 2. ) 36, 37 . It has been recognized already in the 1980s that the enzymatic cascade of the KP generates several neuroactive compounds 38, 39 . The first, rate-limiting step of the KP is the enzymatic degradation of Trp, The other branch of the KP begins with the conversion osf KYN by kynurenine-3-monooxygenase (KMO) into 3-hydroxy-kynurenine. This is further metabolized by multiple enzymatic steps, gives rise to the neurotoxic quinolinic acid (QUIN) and finally ends at the production of the essential coenzyme nicotinamide adenine dinucleotide (NAD). 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 site, but at a higher concentration it can also bind to the glutamate-binding site 41, 42 . On another type of glutamate receptors, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, KYNA exerts a concentration-dependent dual effect: in a higher, micromolar concentration it is an inhibitor, while in a nanomolar concentration it acts as a facilitator 43, 44 . KYNA has also been described to be a non-competitive inhibitor of the presynaptic α7 nicotinic acetylcholine receptors thereby reducing presynaptic glutamate release 45, 46 . Later investigations could not confirm this inhibitory potential 47 . However, KAT-deletion and consequently a loss of KYNA resulted in an increased sensitivity of α7 nicotinic acetylcholine receptors, suggesting a regulatory role of KYNA on them 48 .
Currently, the possible role of KYNA on α7 nicotinic acetylcholine receptors is not clearly understood and further research is needed to describe any potential effect 49 .
It was subsequently confirmed that KYNA is an agonist of the previously orphan G-protein coupled receptor GPR35, which has also been suggested to contribute to the reduction of extracellular glutamate in the brain 50, 51 . The complex modes of actions suggest that KYNA has an important neuromodulatory role in the central nervous system and it is involved in the regulation of glutamatergic and cholinergic neurotransmission ( Table 2. ). [52] [53] [54] [55] . On the other hand, QUIN is a neurotoxic compound which exerts its deteriorating effect mainly via NMDA agonism, but also contributes to the generation of free radicals, promotes lipid peroxidation and decreases antioxidant capacity [56] [57] [58] [59] [60] . Interestingly, in contrast with KYNA, QUIN enhances glutamate release 61 . This effect is suggested to be mediated predominantly by the α7-nicotinic acetylcholine receptors, but at higher concentrations this effect may be due to the inhibition of glutamate receptors 62, 63 . Conversely, levodopa substitution has also been confirmed to reduce KYNA levels 64 . (Fig. 3.) These results further strengthen the concept that KYNA has an important role in the regulation of glutamatergic, cholinergic and dopaminergic neurotransmission, which may also have important implications for the pathophysiology of PD. Alterations of KYNA are able to modulate DA levels, while reduced KYNA levels may also increase vulnerability towards excitotoxic effects by enhancing glutamatergic influences. 65 Alterations in the delicate balance of neuroactive kynurenines have been confirmed in several neurodegenerative diseases, including Alzheimer's disease, multiple sclerosis and Huntington's disease [66] [67] [68] [69] . KP changes have also been described in PD. Kynurenine/Trp ratios were increased, while serum Trp levels were decreased in PD patients as compared with healthy controls 70 . Ogawa et al.
have measured reduced concentrations of KYN and KYNA in several brain regions of PD patients, including the frontal cortex, putamen and substantia nigra 71 . They also confirmed a significantly increased 3-OH-KYN levels in the putamen and substantia nigra of PD brains; this compound may contribute to the oxidative stress and consequently to the neuronal damage 71 . KP alterations have also been measured at the periphery: in the plasma of PD patients, the KYNA level and the KAT activity have been found to be decreased 72 . [73] [74] [75] [76] . Case reports suggested that memantine may also improve LID 77, 78 . So far there is no data concerning its therapeutic effect on non-motor symptoms or ICDs.
Another anti-glutamatergic agent, amantadine has been confirmed to improve LID symptoms both as acute and as chronic therapy [79] [80] [81] . It was proved that the beneficial effect of amantadine is long-lasting, and is sustained even after 1 year of continuous therapy 82 . The beneficial effect of amantadine on LID is suggested to be modulated at least in part by NMDA inhibition 83 . Amantadine has been already tested for the therapeutic management of ICDs with promising results. A small study has revealed that amantadine is capable of reducing pathological gambling in PD patients 6 . The effect of amantadine was recently confirmed by another small-scale study, which described the behavioral background of this effect 84 . The possible therapeutic effect of amantadine was strengthened by other studies involving patients with pathological gambling without PD 85 . Case reports have described the beneficial effect of amantadine on punding as well, which is another complication of dopamine-replacement therapy 86, 87 .
These results suggest that anti-glutamatergic therapies may be valuable options for the management of not only the motor symptoms, but also of the therapy-related complications of PD. KYNA is the only known endogenous NMDA antagonist, which has been suggested to provide symptomatic treatment and also neuroprotection 88, 89 .
In an experimental PD model, KYNA was able to alleviate parkinsonian motor symptoms 89 . There is growing evidence indicating that the hypersensitivity of NMDA receptors plays an important role in the development of LID and other complications of PD, and the NMDA antagonist KYNA may therefore be beneficial for the treatment of these complications too. Elevation of the brain KYNA levels has been already examined in experimental PD models. KYNA itself can cross the blood-brain barrier poorly, but the peripheral administration of its precursor, KYN, together with the organic acid transport inhibitor probenecid, results in significant brain KYNA content elevations. This treatment proved to be neuroprotective in a 6-hydroxydopamine model of PD 88 . Another possibility is the synthesis of kynurenine derivatives, in another animal model of PD, the neuroprotective effects of several synthetic kynurenines were confirmed 90 . Another option to achieve a KYNA elevation would be to influence the enzymatic machinery of the KP; accordingly, KMO inhibition results in a shift .
There are not yet data regarding the effects of KYNA on the non-motor complications of PD, but the promising results with amantadine, and the fact that KYNA is able to improve LID, suggest that KYNA may be of therapeutic value for these conditions too. Further investigations are worth considering to assess the potential therapeutic benefits of KYNA in PD. From this aspect it is of interest to produce synthethic KNYA derivatives which may have more favourable pharmacokinetic properties than those of KYNA, such as an improved receptor selectivity or an improved blood-brain barrier penetration. Several synthethic KYNA analogues have already been developed to achieve neuroprotection 93 .
Syntheses of kynurenic acid derivatives
The general procedure for the synthesis of 4-hydroxyquinolinic acid can be achieved by a modified Conrad-Limpach method starting from the commercially available substituted aryl amines 1 93, 94 . The first step involves enamine bond formation by using dimethyl acetylenedicarboxylate or diethyl acetylenedicarboxylate resulting in 2 (Scheme 1). The aim in the last few years has been to introduce a cationic centre in the side-chain so as to have good water solubility and better penetration ability of the products trough the bloodbrain barrier 94 .
The coupling between KYNA and 2-dimethylaminoethylamine was first achieved by using N,N'-diisopropylcarbodiimide in the presence of 1-hydroxybenzotriazole hydrate, yielding 5 (Scheme 2).
Scheme 2.
The excellent biological activity of 5 led us to prepare a number of analogues 93, 94 . Several of them is shown in Scheme 2. For example, by using 2-diethylaminoethylamine as starting amine, 6 was synthesized as a diethyl analogue of 2 (Scheme 2), and analogues 7, 8 and 9, containing the tertiary nitrogen in different ring systems, were prepared by reacting KYNA with 2-pyrrolidinoethylamine, 2-piperidinoethylamine and 2-morpholinoethylamine, respectively.
The synthethic KYNA analogues have already been tested in several animal models of neurological diseases with promising results 95, 96 . In an animal model of transient global forebrain ischaemia, KYNA exerted a neuroprotective effect by reducing the hippocampal CA1 pyramidal cell loss. The analogue was effective both as a pretreatment and as post-treatment 96 . In a transgenic mice model of Huntington's disease, the same analogue proved not only to ameliorate the motor symptoms but it also significantly, by more than 30%, prolonged the survival of the animals. The neuroprotective effect was also confirmed histologically: the KYNA analogue was able to 
Conclusion
The therapeutic management of PD through dopamine replacement is associated with therapyrelated complications, which may have a more severe impact on the quality of life of patients than the parkinsonian motor symptoms. Alterations of the glutamatergic neurotransmission are implicated in the development of both LID and ICDs, and antiglutamatergic interventions may therefore be beneficial for these complications. KYNA as an NMDA antagonist compound, which is also able to influence dopaminergic neurotransmission may be a promising candidate for future drug development. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
